Choi MH, et al. - In the detection of clinically significant cancer (CSC), researchers assessed the diagnostic performance of the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) with respect to prebiopsy MRI with and without dynamic contrast enhancement. In a retrospective study conducted at two institutions, a total of 113 patients with prostate cancer who had radical prostatectomy and prebiopsy multiparametric 3-T MRI (mpMRI), including T2-weighted imaging, DWI, and dynamic contrast-enhanced MRI (DCE-MRI) were enlisted. Data reported that CSC was identified in 74.3% of patients. Investigators found that the diagnostic performance of prebiopsy bpMRI without DCE-MRI was similar to that of mpMRI with DCE-MRI for detecting CSC.